StockNews.com Initiates Coverage on Athersys (NASDAQ:ATHX)

by · The Cerbat Gem

StockNews.com started coverage on shares of Athersys (NASDAQ:ATHX – Free Report) in a research report released on Tuesday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Athersys Stock Performance

The company has a market cap of $833,000.00, a price-to-earnings ratio of -0.01 and a beta of -0.90. Athersys has a 12 month low of $0.01 and a 12 month high of $1.99.

Athersys Company Profile

(Get Free Report)

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.

See Also